Hutchmed China SANOVO trial shows significant PFS benefit
Hutchmed China Ltd says its SANOVO trial demonstrated significant PFS benefit.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Hutchmed says SANOVO trial shows PFS benefit with ORPATHYS+TAGRISSO in China
Hutchmed said its SANOVO trial showed a progression-free survival benefit for ORPATHYS plus TAGRISSO in treatment-naïve patients with MET-overexpressing EGFR-mutated lung cancer in China.